Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Steffan T. Nawrocki(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center), Jennifer S. Carew(University of Arizona), Ronan Swords(University of Miami), Kelli Oberheu(The University of Texas at San Antonio Health Science Center), Claudia M. Espitia(The University of Texas System), Juan Esquivel(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Monica Mita(Novartis (Switzerland)), Alain C. Mita(Cedars-Sinai Medical Center), Sabrina Smith(The University of Texas at San Antonio Health Science Center), Kevin R. Kelly(Keck Hospital of USC)
Cited by 121
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782